Bradley Thompson, a Member of the Firm in the Health Care and Life Sciences Practice in the Washington, DC office, was quoted in an article about regulatory issues raised by convergent medical technologies.
In the article, “Transformative Technologies Emerge When Worlds Collide,” Thompson recommended that companies be active in advocacy and should make sure to comment on regulatory proposals by the Federal Drug Administration.
During the comment period, it will be incumbent on the companies to identify those things that aren’t practical and to raise constructive solutions,” he noted.
Thompson also recommended that companies communicate with other businesses in the same industries to learn how they handle regulatory issues.
The most cost-effective technique for ensuring compliance and ensuring that products arer same and effective is to share best practices,” he said.